United Therapeutics Co. (UTHR) CEO Sells $2,421,175.60 in Stock
United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 21,512 shares of the firm’s stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $112.55, for a total value of $2,421,175.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Shares of United Therapeutics Co. (NASDAQ:UTHR) traded down $2.01 during midday trading on Wednesday, reaching $111.88. The company’s stock had a trading volume of 373,708 shares, compared to its average volume of 459,948. United Therapeutics Co. has a 1 year low of $107.82 and a 1 year high of $152.55. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 3.01. The firm has a market capitalization of $5,018.83, a price-to-earnings ratio of 11.98 and a beta of 1.32.
United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $3.89 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.59 by $0.30. United Therapeutics had a return on equity of 24.41% and a net margin of 24.22%. The firm had revenue of $464.70 million for the quarter, compared to analyst estimates of $420.55 million. During the same period last year, the company earned $4.12 earnings per share. The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. equities research analysts predict that United Therapeutics Co. will post 12.46 earnings per share for the current year.
Several brokerages recently issued reports on UTHR. ValuEngine cut United Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 27th. BidaskClub cut United Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, February 24th. Barclays restated an “underweight” rating and set a $105.00 price objective (down from $115.00) on shares of United Therapeutics in a research note on Thursday, February 22nd. Credit Suisse Group restated an “underperform” rating and set a $115.00 price objective (down from $120.00) on shares of United Therapeutics in a research note on Thursday, February 22nd. Finally, Zacks Investment Research upgraded United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 price objective on the stock in a research note on Monday, January 15th. Five investment analysts have rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $135.20.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.